Abstract: Metal-driven self-assembly afforded am ultitude of fascinating supramolecular coordination complexes (SCCs) with applications as catalysts,h ost-guest, and stimuli-responsive systems.H owever,t he interest in the biological applications of SCCs is only starting to emerge and thorough characterization of their behavior in biological milieus is still lacking. Herein, we report on the synthesis and detailed in-cell tracking of aP t 2 L 2 metallacycle.W es howt hat our hexagonal supramolecule accumulates in cancer cell nuclei, exerting adistinctive blue fluorescence staining of chromatin resistant to UV photobleaching selectively in nucleolar G4-richr egions. SCC co-localizes with epitopes of the quadruplex-specific antibody BG4 and replaces other well-known G4 stabilizers. Moreover,the photophysical changes accompanying the metallacycle binding to G4s in solution (fluorescence quenching, absorption enhancement) also take place intracellularly,allowing its subcellular interaction tracking.
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The thoughtful choice of transition metals and multidentate ligands allows for the generation of an umber of selfassembled supramolecular coordination complexes (SCCs) with intriguing geometries and attractive properties,including optical, sensing,a nd catalytic. [1] [2] [3] Despite the extraordinary growth of the chemistry of SCCs,s tudies reporting on their potential biomedical applications are so far extremely limited. Recently,s ome research groups have started to exploit the cavity-cored nature of 3D metallacages to develop innovative drug delivery systems. [2, [4] [5] [6] We and others focused our efforts on the intrinsic anticancer potential of SCCs, [5] devoting particular attention to those supramolecules where platinum drives the self-assembly. [7] [8] [9] [10] Pt-ensembles can in principle be designed to mimic complex cellular regulatory motifs.Therefore,they can act through unusual modes of action potentially capable to overcome the drawbacks (for example resistance) of clinically applied Pt II drugs. [11] Nevertheless,a part from preliminary reports on their cytotoxic activity,d etailed information about the in-cell fate of Pt-SCCs is still missing.
In this regard, Stang and Olenyuk reported on the intracellular localization of two emissive Pt II metallacycles. [12] Their compounds were proposed to accumulate in lysosomes of cancer cells producing low toxicity,yet effectively inducing tumor shrinkage in mouse xenograft models. [12] Stang and his team also developed theranostic nanoconstructs incorporating platinum metallacages that displayed in vivo anticancer activity. [13, 14] Afurther demonstration of the potential of Pt II -SCCs in biomedicine was provided by Sleiman and Mao,who discovered that Pt II -based metallacycles display fairly good ability to bind DNAG -quadruplexes (G4s) in solution. [15] [16] [17] [18] G4s are non-canonical DNA/RNAmotifs enriched in important regulatory regions, [19] and regarded as emerging targets for anticancer drugs. [20] They recently achieved a"star" status due to their subcellular visualization using G4-specific antibodies. [21, 22] Furthermore,two G4 binders (CX-3543 and CX-5461) have entered advanced clinical trials for human cancers. [23, 24] In this context, we have recently reported on the promising DNAb inding profiles of 4,4'-bipyridine-based dinuclear Pt II metallacyles. [25] Our SCCs,w hilst not particularly cytotoxic (IC 50 ! 40 mm), distinctly influence the expression of genes known to contain quadruplex motifs in their promoters, with potency and selectivity which well correlate with the size of the supramolecules. [25] Herein, we report on an ew hexagonal dinuclear Pt II metallacycle (1,F igure 1) designed to have DNA-binding capacity and favorable optical properties for tracking its in-cell fate when bound to different nucleic acid structures.
Over the past few years we have developed astraightforward strategy for the self-assembly of dinuclear Pt II -based metallacycles. [26] Inspired by recent works of Wasielewski and Stoddart on cyclophanes bearing isolated phenyl-extended viologen moieties, [27, 28] we argued that the ditopic pyridyl ligand L1 (Figure 1a )w ould confer an adequate emission profile to the final supramolecule and overcome quenching effects typical of SCCs. [29] [30] [31] Theh ighly emissive biphenylextended viologen moiety ( Figure 1 , in turquoise) would maintain al igand-centered emission profile when incorporated in the corresponding dinuclear Pt II -metallacycle 1 due to the non-direct connectivity to the metal centers.F urthermore,the dimensions (ca. 200 2 )and the octacationic nature of 1 are quite similar to those of our previously reported DNA/quadruplex binders, [25] af act that we envisaged would translate as well into ac omparable DNA-binding profile. Synthesis of 1 was carried out according to methodologies previously reported by us for similar SCCs (see Supporting Information for details). [32] Steady-state 3D excitation-emission spectra (Supporting Information, Figure S1a ,b) showed that 1 buffered solutions emit in the blue with am aximum at 445 nm when excited at 360 nm (an absorption band ascribed to p-p*t ransitions of the biphenyl moiety). Thef luorescence profile of 1 is rather similar to the one of its ligand L1, whose emission maximum is slightly blue-shifted (l max = 437 nm, Figure S1b in the Supporting Information). This,together with the observation that both 1 and L1 have emission lifetimes of about 2-3 ns (Supporting Information, Figure S1c ), suggest that fluorescence is mainly dependent on the excited states of the ligand, as reported likewise for other Pt II -SCCs. [12] Even though ligand L1 is more emissive in water than 1 (f F = 0.84 at 437 nm, Figure S2 in the Supporting Information), the metallacycle has as urprisingly good quantum yield in water (f F = 0.38 at 445 nm). This finding is in sharp contrast to what has been recently observed for other platinum-based cages which display high emission only in non-polar solvents. [33] Such an aspect is particularly important for SCCs biological applications,m aking 1 ag ood candidate for tracking the cellular distribution of this class of compounds.
After proving by NMR and UV/Vis spectroscopy that 1 is stable overtime in water, buffered solutions,a nd cell culture media (with or without fetal bovine serum) (Supporting Information, Figure S3 ), we explored the interaction of the metallacycle with different DNAsequences including duplex DNAa nd G4 models.F RET,U V/Vis,f luorescence,a nd circular dichroism assays showed that 1 is able to strongly bind both duplex and quadruplex DNAs,w ith moderate preference for parallel G4s (see Supporting Information and Figure S4 -S7 for ad etailed discussion), similarly with what was observed for other Pt-SCCs prepared by us previously. [25] We then investigated the applicability of our newly synthesized Pt-compound in biological settings,e valuating its impact on the viability of non-transformed human keratinocytes and human lung fibroblasts (HaCaT and HLF) as well as of cancer cell models derived from different primary origins including breast cancer, osteosarcoma, melanoma, and glioblastoma ( Figure 2a and Table S1 in the Supporting Information). While HaCat cells were completely resistant against the cytotoxic impact of the metallacycle,the activity against highly proliferative HLF was comparable to malignant cell types,where 1 showed IC 50 values in the range 30-45 mm after 72 ho fi ncubation, with MCF-7 and U2OS being the most sensitive models.L igand L1 was slightly less active and followed the same trend (Supporting Information, Figure S8a and Table S1 ). These results are in good agreement with the general low cytotoxicity of similar Pt-SCCs observed earlier by ourselves and Olenyuk. [12, 25] Combination of 1 with cisplatin in MCF-7 cells (Supporting Information, Figure S8b ) gave rise to aslightly antagonistic effect suggesting that they may share mutual targets (nucleic acids) but exert adiffering mode of action. MCF-7 and U2OS cell sensitivity to 1 was also tested through clonogenic assay,s electing al onger incubation time (7 days). Both cell lines showed impaired colony formation upon incubation with 1 at already 15-20 mm (Supporting Information, Figure S9 ). Interestingly,t he long-term treatment had as tronger impact on U2OS compared to MCF-7 cells (15 mm vs.2 0mm,r espectively). Conversely,c ell cycle distribution analysis revealed that after 24 hincubation there was asignificant dose-dependent cell accumulation in G0/G1 phase and clear-cut cell death induction only in MCF-7 cells, while U2OS cell populations presented no appreciable changes at this comparably short incubation time (Supporting Information, Figure S10 ).
To elucidate whether 1 indeed targets G4 regulated genes, whole genome gene expression analyses were performed on U2OS cells comparing the impact of the metallacycle with that of pyridostatin (PDS), aw ell-known G4 stabilizer. [21] Gene set enrichment analysis (GSEA) clearly revealed that 1 preferentially targets genes located in chromosomal regions enriched in G4 structures [34] with multiple KEGG terms similarly suppressed or activated by 1 and PDS (Supporting Information, Figure S11 a-c).
Confocal laser scanning microscopy (CLSM) was used to evaluate 1 subcellular emission fingerprint. MCF-7 cells treated with 1 revealed an intense blue fluorescence signal in the range 420-518 nm (l exc = 405 nm, Figure 2b and S12 in the Supporting Information), showing an early perfect overlap with the emission band obtained in cell-free conditions (Figure 2b ). Flow cytometry analysis of 1-treated U2OS cells nicely confirmed CLSM results.P t-SCC 1 gave rise to ac onsiderable emission in the blue portion of the spectrum (l exc = 405 nm) (Supporting Information, Figure S13a) . Interestingly, 1-associated emission decreased when cells were treated concomitantly with PDS suggesting G4s involvement. [21] In contrast it was unaffected by combination with cisplatin indicating ad ifferent binding mechanism (Supporting Information, Figure S13b ). In CLSM analyses as well as in FACS experiments, L1 emission was considerably lower. FACS,f or example,d isplayed ad rastic reduction of the blue fluorescence of 94 %f or L1 at l exc = 405 nm (Supporting Information, Figure S13 ). Theefficiency of 1 emission in cell can be attributed to the increased rigidity imposed by the metallacycle to the biphenyl-extended fluorophore. [28] FACS analysis of U2OS cells treated with 1 showed as ignificant drug accumulation within the first hour of incubation, while L1 did not share the same accumulation features (Figure 2c) . Live cell imaging indicated that exposure of U2OS cells to compound 1 at 35 mm produced an increase in fluorescence overtime (Supporting Information, Figure S14 ) which nicely corroborates FACS results.T he emission of the ligand was in this case below the detection limit of the instrument (Supporting Information, Figure S15) . Crucially,the different emissive behavior of L1 compared to 1,o bserved using diverse experiments and techniques,s uggests ad ifferent trafficking dynamic inside the cells for the two compounds and allows ruling out possible cellular decomposition of the platinum ensemble to its free building blocks.
Drug distribution within cells was further studied by CLSM. Super-resolution airy-scan images of U2OS cells fixed with MeOH and incubated with 1 showed as tructured blue staining of the whole nucleus confirming binding of 1 to DNA. Extended UV exposure,however,produced aphotobleaching effect which was dependent on the sub-nuclear region. Hence, at G4-rich loci, 1 photobleaching was distinctly less efficient resulting in the labelling of nucleoli-like substructures (Figure 2d) . This effect was corroborated by time-lapse fluorescence microscopy (Supporting Information, Figure S16 ). Confocal micrographs of U2OS and MCF-7 cells fixed with paraformaldehyde (PFA) confirmed the pan-nuclear blue fluorescent staining induced by 1 (Figure 2e and S17a in the Supporting Information). Interestingly,i mages of fixed cells exposed to 1, acquired using DIC (differential interference contrast) mode,r evealed as trong contrast enhancement of nuclei and ac lear-cut "dark" staining of the nucleoli-like substructures (see below). This unique effect is independent of the fixation method since MCF-7 cells fixed with methanol gave the same outcome ( Supporting Information, Figure S17b) . Such acontrast enrichment effect was not detected when cells were incubated with L1 or DAPI, ac onventional nuclear DNAs tain (Supporting Information Figure S17a ).
To have af irst hint about possible interaction of 1 with G4s in cells,fluorescence competition assays were performed and analyzed by live cell imaging microscopy.The G4-binders TMPyP4 and Thioflavin-T (ThT) were used since they are also intracellularly fluorescent. In detail, TMPyP4 is an onselective porphyrin-based binder displaying ared emission, [35] while ThTi sk nown for its green fluorescent, G4-selective, light-up effect both in solution [36] and in cells. [37] MCF-7 cells incubated with the porphyrin and 1 showed an initial TMPyP4-associated red fluorescence localized in the nuclei that turned blue overtime (Supporting Information, Figure S18a and Video S1). Thes ame effect was obtained with ThT/1 incubation, with the ThT-associated nucleolar green emission being replaced by the blue signals induced by 1 (Supporting Information, Figure S18b and Video S2). This outcome clearly indicated that 1 acts as competitor of both TMPyP4 and ThTf or the same binding sites (duplex and G4s), showing an enhanced long-term target affinity.I ti s worth noting that live cell imaging was affected by considerable cell death after treatment with 1,p robably based on phototoxicity or synergistic effects when combined with TMPyP4 and ThT. We verified the latter hypothesis through viability assays,d emonstrating that co-incubations of 1 with ThT( or PDS) produced strong synergistic cytotoxicity in MCF-7 and U2OS cells ( Supporting Information, Figure S18c) .
Ac ompetition assay was also performed in cells fixed after ThTexposure.M etallacycle 1 blocked the G4-selective green fluorescence staining of nucleoli by ThT (Figure 3a and S19a in the Supporting Information), comparable to recent reports for PDS. [37] Similarly, 1 completely displaced the green nucleoli marker SYTO RNASelect (SYTO,F igure 3b), while it did not interact with mitochondrial labelling by MitoTracker Red (MR, Figure S19b in the Supporting Information).
To further evaluate that cellular distribution of 1 could be governed also by the presence of G4s besides duplex DNA, aseries of immunofluorescence studies using the quadruplex specific antibody BG4 [21, 22] was performed (Figure 3c -e). Fluorescence microscopy images of MeOH-fixed MCF-7 cells were acquired after BG4 immunofluorescence and subsequent 1 staining at extended UV exposure(photobleaching). We then repeated BG4 co-localization experiments, taking advantage of the clear-cut "dark" staining of subnuclear structure observed previously for compound 1. CLSM images of MeOH fixed MCF-7 cells (Figure 3d )p roves that, also in this case, 1 co-localized with the anti-G4 immunostaining by BG4. In detail, our Pt-SCC labelled the whole nucleus with ab lue fluorescence and rendered nuclear substructures visible in the DIC channel as dark stains.B G4 revealed red signals exactly in the same regions (l exc = 555 nm) as depicted from representative pixel intensity plots of fluorescence and DIC images (Supporting Information, Figure S20 ). It should be noted that BG4 epitope distribution is known to be dependent on the fixation method used. Recent studies reported that the antibody labels preferentially nucleoli when MeOH is used for fixation. [38] Hence,our experiments indicate that Pt-metallacycle 1 actually targets G4-rich nucleolar structures.T he co-labelling assays were repeated both changing either the incubation order or the fixation method. When MCF-7 cells were fixed with MeOH, incubated with 1 and then with the antibody,aloss of BG4 staining in the nucleoli was produced (Supporting Information, Figure S21a ). Them icrographs showed instead aw eak overall red labelling within the cytoplasm. Theo utcome was similar when living cells were pre-treated with 1,t hen fixed and finally labelled with BG4 (Supporting Information, Figure S21b ). Additionally,c omparable displacement effects were obtained when MCF-7 cells were fixed with PFA. Incubation with BG4 produced the classic nuclear red punctate staining pattern (Figure 3e and Figure S22 in the Supporting Information) as reported by Biffi et al. [21, 22] When PFA-fixed cells were pre-treated with 1,t he BG4 punctate pattern got diffused, appearing enriched in the cytoplasm, demonstrating that metallacycle 1 disrupted BG4 ability to stain G4s in the nuclear region. Eventually,c o-incubation of 1 and BG4 rendered comparable results at the level of individual chromosomes,obtaining the same effect (Supporting Information, Figure S23d) .
Overall, these experiments clearly indicate that 1,o nce inside the nucleus (and the nucleoli), interacts with nucleic acids and interferes with the G4 epitope recognition by BG4.
Besides its cellular co-localization with BG4 and its emissive properties,o ur Pt-metallacycle showed the unique ability to provide well-contrasted images of cells in transmission (monochrome) DIC mode.The brightfield channel is often ignored in drug accumulation studies for several reasons (poor contrast, difficult localization of cell borders,f aint nuclei and others). [39] Nevertheless,w ew ere particularly intrigued by the clear-cut and intense dark staining of nucleoli provided by 1,w hich resulted to be easily reproducible and independent of the fixation method and cell line used.
Considering the complex optical mechanism at the basis of DIC microscopy, [40] we hypothesized that the dark nucleolar "staining" could arise from absorption or refraction (or both) of the light by the Pt-metallacycle within the subnuclear structures,a ssociated to as imultaneous quenching (and photobleaching resistance) of its blue fluorescence.T he UV/Vis spectrum of 1 in solution showed ab and centred at 355 nm with at ail ending at around 430 nm (Figure 4a) . Interestingly,the absorbance at 355 nm was significantly redshifted when aliquots of pre-folded parallel quadruplex were added, resulting in ac onsiderable increase in absorption at 405 nm (Figure 4a ). This effect was noticeably less pronounced when the same experiment was performed using ad ouble-stranded DNAm odel (Supporting Information, Figure S5b ). At the same time,astrong fluorescence quenching was observed after interaction of 1 with the same parallel G4 in solution (Figure 4b ). Crucially,t he quenching was less pronounced after the interaction with ds-DNA, as confirmed by the binding and the Stern-Volmer constants lower in two and one orders of magnitudes,r espectively (Supporting Information, Figure S6) .
Furthermore,M CF-7 cells fixed with MeOH and incubated with 1 afforded cell images with dramatically enhanced contrast in the DIC setting with 405 nm excitation (where the metallacycle-G4 adduct preferentially absorbs light, Figure 4a) , depicting prominently visible nucleoli (Figure 4c,d) . When changing the excitation wavelength to 488 nm, just faint cell contours typical for DIC remained visible (Figure 4e) . Of note,n ucleoli staining was not observed when fixed MCF-7 cells were incubated with another Pt-SCC, selected among our toolbox of metallacycles because of its transparencya t405 nm ( Supporting Information, Figure S24 ). Likewise,s taining of fixed MCF-7 cells with DAPI resulted in the expected blue chromatin staining without any contrast enhancement in the DIC setting.W hile nucleoli remained invisible in absorption imaging,t hey appeared darker in the blue fluorescence channel based on the wellknown binding of DAPI to AT-rich regions (Supporting Information, Figure S25 ).
These considerations strongly suggest that the dark staining is produced by absorption of 1 interacting with G4 structures within the nucleoli in association with initial distinct fluorescence quenching.
In summary,w et horoughly described the intracellular fate of aP t-SCC.B ased on its fluorescence properties,w e show,for the first time for aPt-based SCC,that 1 is taken up by cancer cells and accumulates in the nucleus.Furthermore, the particular alterations of the metallacycle optical features when interacting with G4 as compared to duplex DNA offered au nique tool for its subcellular interaction profiling.C ompound 1 preferentially targets nucleolar structures,c o-localizes with aG 4-specific antibody and displaces well-known G4 stabilizers.O ur insolution and cellular results,together with the information that nucleoli are particularly rich in G4 forming sequences, [38, [41] [42] [43] strongly support that these noncanonical nucleic acid structures are also the final target of the Pt-SCC.Q uarfloxin (CX-3543), the first-in-class G4-binder in clinical trials,i sb elieved to exert its anticancer activity through as imilar mechanism, that is,precisely by accumulation in nucleoli. [23] To conclude, platinum-based SCCs are an extremely versatile class of compounds with the potential to mimic recognition properties of complex biological systems.T his manuscript provides evidence that nucleic acids, and in particular G-quadruplex structures,c an be key cellular targets of platinum-driven supramolecular coordination compounds.O ur findings open new avenues in the development of anticancer platinum-based SCCs with promising and defined mechanisms of action. 
